Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

[1]  C. Colosimo,et al.  Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[2]  P. Riederer,et al.  Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum , 2003, Journal of Neural Transmission.

[3]  F. Jiménez-Jiménez,et al.  Possible Zoophilia Associated with Dopaminergic Therapy in Parkinson Disease , 2002, The Annals of Pharmacotherapy.

[4]  A. Lees,et al.  Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies , 2000, Journal of neurology, neurosurgery, and psychiatry.

[5]  P. Sokoloff,et al.  Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. , 1999, European journal of pharmacology.

[6]  H. Fernandez,et al.  Clozapine for dopaminergic‐induced paraphilias in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[7]  B. Levant.  The D3 dopamine receptor: neurobiology and potential clinical relevance. , 1997, Pharmacological reviews.

[8]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[10]  C. Goetz,et al.  Hypersexuality with antiparkinsonian therapy. , 1989, Clinical neuropharmacology.